Abstract
The presence of a t(4;14) in multiple myeloma (MM) is associated with significantly inferior outcomes following both conventional chemotherapy and high-dose melphalan-based treatment regimens.1, 2 Detection of patients bearing the t(4;14) is therefore important in an MM molecular workup. Furthermore, since targeted inhibitors of the associated fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase are now in clinical trials,3 detection of MM patients who express the FGFR3 protein is also of potential therapeutic relevance. With this in mind, we have employed the infrastructure of the Multiple Myeloma Research Consortium (MMRC) tissue bank to evaluate four different methodologies for the molecular diagnostic detection of this translocation. The methods employed are published previously4, 5, 6 or are provided as Supplementary Information.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
